Patients with seizure disorders have an increased incidence of depression. This may be due in part to psychosocial factors, or side effects of antiepileptic drugs. However, there may be underlying physiologic mechanisms for the relationship. Neuroimaging studies, including structural magnetic resonance imaging, positron emission tomography measurements of cerebral glucose metabolism, and, more recently, imaging of serotonin 1A receptors, may provide additional data to explain overlapping clinical manifestations of epilepsy and depression.
HardenC.The co-morbidity of depression and epilepsy: Epidemiology, etiology, and treatment. Neurology2002;59(suppl4): S48–S55.
2.
KannerAMBalabanovA.Depression and epilepsy: How closely related are they?Neurology2002;58(suppl5): S27–S39.
3.
MorrellMJPedleyTA. ‘The scarlet E’ - epilepsy is still a burden. Neurology2000;54:1882–1883.
4.
MeadorKJGilliamFGKannerAMPelloclPM. Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav2001;2(suppl): SS1–SS18.
5.
AltshulerL.Depression and epilepsy. In: DevinskyOTheodoreWH (eds). Epilepsy and Behavior. New York: Wiley-Uss; 1991: 47–66.
6.
AltshulerLLDevinskyOPostRMTheodoreW.Depression, anxiety, and temporal lobe epilepsy: Laterality of focus and symptoms. Arch Neurol1990;47:284–288.
7.
QuiskeAHelmstaedterCLuxSElgerCE. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res2000;39:121–125.
8.
JacobyABakerGASteenNPottsPChadwickDW. The clinical course of epilepsy and its psychosocial correlates: Findings from a UK community study. Epilepsia1996;37:148–161.
9.
HesdorfferDCHauserWAAnnegersJF. Major depression is a risk factor for seizures in older adults. Ann Neurol2000;47:246–249.
10.
EnnapadamKrishnamoorthy S. Psychiatric issues in epilepsy. Current Opinion in Neurology2001;14(2): 217–224.
11.
StevenSchachter C. Vagus nerve stimulation therapy summary: Five years after FDA approval. Neurology2002;59(suppl4): S15–S20.
12.
TheodoreWHHunterKChenRVega-BermudezFBoroojerdiBReeves-TyerR. Transcranial magnetic stimulation for the treatment of seizures: A controlled study. Neurology2002;59:560–562.
13.
BurtTLisanbySHSackeimHA. Neuropsychiatric applications of transcranial magnetic stimulation: A metaanalysis. Intl J Neuropsychopharmacol2002;5:73–103.
14.
GeorgeMSNahasZBohningDEKozelFAAndersonBChaeJ.-H. Vagus nerve stimulation therapy: A research update. Neurology2002;59(suppl): S56–S61.
15.
SuppesT.Review of the use of topiramate for treatment of bipolar disordersJ Clin Psychopharmacol2002;22:599–609.
16.
GilliamFMatonBMartinRC. Extent of 1H spectroscopy abnormalities independently predicts mood status and quality of life in temporal lobe epilepsy. Epilepsia2000;41(suppl7): 54.
17.
BendabisSRTatumWOMurtaghFRValeFL. MRI evidence of mesial temporal sclerosis in patients with psychogenic nonepileptic seizures. Neurology2000;55:1061.
18.
van ElstTebartz LWoermannFGLemieuxL. Affective aggression in patients with temporal lobe epilepsy: A quantitative MRI study of the amygdala. Brain2000;123:234–243.
19.
van ElstTebartz LWoermannFGLemieuxLTrimbleM.Amygdala enlargement in dysthymia: A volumetric study of patients with temporal lobe epilepsy. Biol Psychiatry1999;46:1614–1623.
20.
TheodoreWH. Neuroimaging and neuropathology in psychiatry and epilepsy. In: DevinskyOTheodoreWH, (eds). Epilepsy and Behavior. New York: Wiley-Liss; 1991: 291–303.
21.
BaxterLRPhelpsMEMazziottaJC. Cerebral metabolic rate for glucose in mood disorders. Arch Gen Psychiatr1985;42:441–447.
22.
BaxterLRJrPhelpsMEMazziottaJCGuzeBHSchwartzJMSelinCE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry1987;44:211–218.
23.
BaxterLRJrSchwartzJMPhelpsME. Reduction of the prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry1989;46:243–250.
24.
KimbrellTAKetterTAGeorgeMSLittleJTBensonBEWillisMW. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry2002;51(3):237–252.
25.
ShelineYLWanyPCgadoMHCsernanskyJGVannierMW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA1996;93:908–913.
26.
KegelesLSMaloneKMSlifsteinMEllisSPXanthopoulosEKeilpJG. Response of cortical metabolic deficits to serotonergic challenge in familial mood disorders. Am J Psychiatry2003;160(1):76–82.
27.
DunnRTKimbrellTAKetterTAFryeMAWillisMWLuckenbaughDA. Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. Biol Psychiatry2002;51(5):387–399.
28.
DrevetsWCVideenTOPriceJLPreskornSHCarmichaelTRaichleME. A functional neuroanatomical study of unipolar depression. J Neurosci1992;12:3628–3641.
29.
BiverFGoldmanSDelvenneVLuxenADe MaertelaerVHubainP. Frontal and parietal metabolic disturbances in unipolar depression. Biol Psychiatry1994;36:381–388.
30.
VidebechPRavnkildeBPedersenTHHartvigHEganderAClemmensenK. The Danish PET/depression project: Clinical symptoms and cerebral blood flow: A regions-of-interest analysis. Acta Psychiatr Scand2002;106(1): 35–44.
31.
SaxenaSBrodyALHoMLAlborzianSHoMKMaidmentKM. Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. Biol Psychiatry2001;50(3): 159–170.
32.
DrevetsWCBogersWRaichleME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol2002;12(6): 527–544.
33.
SmithGSMaYDhawanVGunduzHCarbonMKirshnerM, Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. Synapse2002;45(2): 105–112.
34.
SmithGSReynoldsCFIIIHouckPRDewMAMaYMulsantBH. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry2002;10(5): 561–567.
35.
MottaghyFMKellerCEGangitanoMLyJThallMParkerJA. Correlation of cerebral blood flow and treatment effects of repetitive transcranial magnetic stimulation in depressed patients. Psychiatry Res2002;115:1–14.
36.
BrodyALSaxenaSMandelkernMAFairbanksLAHoMLBaxterLR. Brain metabolic changes associated with symptom factor improvement in major depressive disorder. Biol Psychiatry2001;50(3): 171–178.
37.
KennedySHEvansKRKrugerSMaybergHSMeyerJHMcCannS. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry2001;158(6): 899–905.
38.
BromfieldEBAltshulerLLeidermanDBBalishMNKetterTADevinskyO. Cerebral metabolism and depression in patients with complex partial seizures. Arch Neurol1992;49:617–625.
39.
VictoroffJLBensonFGraftonSTEngelJJrMazziottaJC. Depression in complex partial seizures: Electroencephalography and cerebral metabolic correlates. Arch Neurol1994;51:155–163.
40.
SchmitzEBMoriartyJCostaDCRingHAEllPJTrimbleMR. Psychiatric profiles and patterns of cerebral blood flow in focal epilepsy: Interactions between depression, obsessionality, and perfusion related to the laterality of the epilepsy. J Neurol Neurosurg Psychiatry1997;62(5): 458–463.
41.
RingHAActonPDScullDCostaDCGacinovikSTrimbleMR. Patterns of brain activity in patients with epilepsy and depression. Seizure1999;8(7): 390–397.
42.
JuhaszCBehenMEMuzikOChuganiDCChuganiHT. Bilateral medial prefrontal and temporal neocortical hypometabolism in children with epilepsy and aggression. Epilepsia2001;42(8): 991–1001.
43.
TheodoreWHBromfieldEOnoratiL.The effect of carbamazepine on cerebral glucose metabolism. Ann Neurol1989;25:516–520.
44.
HallHLundkvistCHalldinC. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res1997;745:96–108.
45.
FletcherAForsterEABillDJ. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635; a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res1996;73:337–353.
46.
PikeWVMcCarronJALammerstmaAA. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. Eur J Pharmacol1995;283:R1–R3.
47.
PikeVWMcCarronJALammerstmaAA. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C] wAY-100635. Eur J Pharmacol1996;301:R5–R7.
48.
LangLJagodaESchmallB. Development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem1999;42:1576–1586.
49.
CarsonRELangLWatabeH. PET evaluation of [18F)FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. Nucl Med Biol2000;27:493–497.
50.
RosierADupontPPeuskensJBormansGVandenbergheRMaesM. Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Res1996;25:68(1): 11–22.
51.
HuangYHwangDRNarendranRSudoYChatterjeeRBaeSA. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652; [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C)AFM. J Cereb Blood Flow Metab2002;22(11): 1377–1398.
52.
HoyerDHannonJPMartinGR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav2002;71:533–554.
53.
BurnetPWJEastwoodSLLaceyKHarrisonPJ. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res1995;676:157–168.
54.
BarnesNMSharpT.A review of central 5-HT receptors and their function. Neuropharmacology1999;38:1083–1152.
55.
LanfumeyLHamonM.Central 5-HT1A receptors: Regional distribution and functional characteristics. Nucl Med Biol2000;27:429–435.
56.
ClarkeWPYoccaFDMaayaniS.Lack of 5-Hydroxytryptamine1A-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats. J Pharmacol Exp Ther1996;277:1259–1266.
57.
Le PoulEBoniCHanounN. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology2000;39:110–122.
58.
MaedaJSuharaTOgawaMOkauchiTKawabeKZhangMR. In vivo binding properties of [carbonyl-11C]WAY-100635: Effect of endogenous serotonin. Synapse2001;40(2): 122–129.
59.
HusseiniKMDrevetsWCCharneyDS. The cellular neurobiology of depression. Nature Med2001;7:541–547.
60.
DrevetsWCFrankEPriceJCKupferDJHoltDGreerPJ. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry1999;46:1375–1387.
61.
SargentPAKjaerKHBenchCJRabinerEAMessaCMeyerJ. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: Effects of depression and antidepressant treatment. Arch Gen Psychiatry2000;57(2); 174–180.
62.
MeyerJHKapurSHouleSDa SilvaJOwczarekBBrownG M. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry1999;156(7): 1029–1034.
63.
MeyerJHMcMainSKennedySHKormanLBrownGMDa SilvaJN. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry2003;160(1): 90–99.
64.
LarischRKlimkeAMayoralFHamacherKHerzogHRVosbergH. Disturbance of serotonin 5HT2 receptors in remitted patients suffering from hereditary depressive disorder. Nuklearmedizin2001;40(4): 129–134.
65.
FujitaMCharneyDSInnisRB. Imaging serotonergic neurotransmission in depression: Hippocampal pathophysiology may mirror global brain alterations. Biol Psychiatry2000; 15; 48(8): 801–812.
66.
YathamLNLiddlePFShiahISScarrowGLamRWAdamMJ. Brain serotonin2 receptors in major depression: A positron emission tomography study. Arch Gen Psychiatry2000;57(9): 850–858.
67.
MessaCColomboCMorescoRMGobboCGalliLLucignaniG. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: A PET study. Psychopharmacology (Berl)2003;167(1): 72–78.
68.
Attar-LevyDMartinotJLBlinJDao-CastellanaMHCrouzelCMazoyerB. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry1999; 15; 45(2): 180–186.
69.
YathamLNLiddlePFDennieJShiahISAdamMJLaneCJ. Decrease in brain serotonin2 receptor binding in patients with major depression following desipramine treatment: A positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry1999;56(8): 705–711.
70.
AudenaertKVan LaereKDumontFSlegersGMertensJvan HeeringenCDierckxRA. Decreased frontal serotonin 5-HT 2a receptor binding index in deliberate self-harm patients. Eur J Nucl Med2001;28(2): 175–132.
71.
IchimiyaTSuharaTSudoYOkuboYNakayamaKNankaiM. Serotonin transporter binding in patients with mood disorders: A PET study. Biol Psychiatry2002;1:51(9): 715–722.
72.
DahlstromMAhonenAEbelingHTorniainenPHeikkilaJMoilanenI.Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents. Mol Psychiatry2000;5(5): 514–522.
73.
MalisonRTPriceLHBermanRvan DyckCHPeltonGHCarpenterL. Reduced brain serotonin transporter availability in major depression as measured by [1231]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry1998;1:44(11): 1090–1098.
BeckSGChoiKC. 5-Hydroxytryptamine hyperpolarizes CA3 hippocampal pyramidal cells through an increase in potassium conductance. Neurosci Lett1991;133:93–96.
76.
OkuharaDYBeckSG. 5-HT1A receptor linked to inward-rectifying potassium current in hippocampal CA3 pyramidal cells. J Neurophysiol1994;71:2161–2167.
77.
WadaYNakamuraMHasegawaHYamaguchiN.Role of serotonin receptor subtype in seizures kindled from the feline hippocampus. Neurosci Lett1992;141:21–24.
78.
WadaYNakamuraMHasegawaHYamaguchiN.Intra-hip-pocampal injection of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) inhibits partial and generalized seizures induced by kindling stimulation in cats. Neurosci Lett1993;159:179–182.
79.
LuKTGeanPW. Endogenous serotonin inhibits epileptiform activity in rat hippocampal CA1 neurons via 5-hydroxytrypta-minelA receptor activation. Neuroscience1998;86:729–737.
80.
SalgadoDAlkadhiKA. Inhibition of epileptiform activity by serotonin in rat CA1 neurons. Brain Res1995;669:176–182.
81.
Salgado-CommissariatDAlkadhiKA. Serotonin inhibits epileptiform discharge by activation of 5-HT1A receptors in CA1 pyramidal neurons. Neuropharmacology1997;36:1705–1712.
82.
GariboldiMTutkaPSamaninRVezzaniA.Stimulation of 5-HT1A receptors in the dorsal hippocampus and inhibition of limbic seizures induced by kainic acid in rats. Br J Pharmacol1996;119:813–818.
83.
StatnickMADaileyJWJobePCBrowningRA. Abnormalities in 5-HT1A and 5-HT1B receptor binding in severe-seizure genetically epilepsy-prone rats (GEPR-9s). Neuropharmacology1996;35:111–118.
84.
DaileyJWYanQSAdams-CurtisLERyuJRKoKHMishraPKJobePC. Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Life Sci1996;58(4): 259–266.
85.
YanQSJobePCDaileyJW. Further evidence of anticonvulsant role for 5-hydroxytryptamine in genetically epilepsy-prone rats. Br J Pharmacol1995;115:1314–1318.
86.
YanQSDaileyJWSteenbergenJLJobePC. Anticonvulsant effect of enhancement of noradrenergic transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): A microinjection study. Brain Res1998;12:780(2): 199–209.
87.
SarnyaiZSibilleELPavlidesCFensterRJMcEwenBSTóthM.Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin 1A receptors. Proc Natl Acad Sci USA2000;97:14731–14736.
TecottLHSunLMAkanaSFStrackAMLowensteinDHDallmanMFJuliusD.Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature1995;374(6522): 542–546.
92.
O'DellLEKreifeldtMJGeorgeFRRitzMC. The role of serotonin (2) receptors in mediating cocaine-induced convulsions. Pharmacol Biochem Behav2000;65(4): 677–681.
93.
YanQS. Reduced serotonin release and serotonin uptake sites in the rat nucleus accumbens and striatum after prenatal cocaine exposure. Brain Res2002;1:929(1): 59–69.
94.
FilakovszkyJGerberKBagdyG.A serotonin-1A receptor agonist and an N-methyl-D-aspartate receptor antagonist oppose each others effects in a genetic rat epilepsy model. Neurosci Lett1999;261(1–2): 89–92.
95.
YanQSYanSE. Serotonin-1B receptor-mediated inhibition of [(3)H]GABA release from rat ventral tegmental area slices. J Neurochem2001;79(4): 914–922.
96.
YanQSYanSE. Activation of 5-HT(1 B/1D) receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: A microdialysis study. Eur J Pharmacol2001;20:418(1–2): 55–64.
97.
YanQSMishraPKBurgerRLBettendorfAFJobePCDaileyJW. Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. J Pharmacol Exp Ther1992;261:652–659.
98.
DaileyJWReithMEYanQSLiMYJobePC. Anticonvulsant doses of carbamazepine increase hippocampal extracellular serotonin in genetically epilepsy-prone rats: Dose response relationships. Neurosci Lett1997;227:13–16.
99.
SouthamEKirkbyDHigginsGAHaganRM. Lamotrigine inhibits monoamine uptake in vitro and modulates hydroxytryptamine uptake in rats. Eur J Pharmacol1998;358:19–24.
100.
ToczekMTCarsonRELangLMaYSpanakiMVDerMG. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology200360: 749–756.
101.
ChuganiDCChuganiHTMuzikO. Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]methyl-L-tryptophan positron emission tomography. Ann Neurol1998;44:858–866.
102.
AsanoEChuganiDCMuzikO. Multimodality imaging for improved detection of epileptogenic foci in tuberous sclerosis complex. Neurology2000;54:1976–1984.
103.
FediMReutensDCAndermannFOkazawaHBolingWWhiteC. Alpha-[11C]-Methyl-L-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency. Epilepsy Res2003;52(3): 203–213.
104.
FediMReutensDOkazawaH. Localizing value of alpha-methyl-L-tryptophan PET in intractable epilepsy of neocortical origin. Neurology2001;57:1629–1636.
105.
JuhàszCChuganiDCMuzikOShahAAsanoEMangnerTJ. Alpha-methyl-l-tryptophan PET detects epileptogenic cortex in children with intractable epilepsy. Neurology2003;60:960–968.
106.
NatsumeJKumakuraYBernasconiNSoucyJ.-PNakaiARosaP. Alpha]-[11C] methyl-L-tryptophan and glucose metabolism in patients with temporal lobe epilepsy. Neurology2003;60:756–761.
107.
ChuganiDCChuganiHT. Does serotonin have trophic effects in temporal lobe epilepsy?Neurology2003;60:736–737.
108.
LarischRKlimkeAHamacherKHenningUEstaljiSHohlfeldT. Influence of synaptic serotonin level on (18F]altanserin binding to 5HT(2) receptors in man. Behav Brain Res2003;17:139(1–2): 21–29.
109.
ZimmerLMaugerGLe BarsDBonmarchandGLuxenAPujolJF. Effect of endogenous serotonin on the binding of the 5-HT1A PET ligand 18F-MPPF in the rat hippocampus: kinetic beta measurements combined with microdialysis. J Neurochem2002;80(2): 278–286.
110.
Van BogaertPDe TiegeXVanderwindenJMDamhautPSchiffmannSNGoldmanS.Comparative study of hip-pocampal neuronal loss and in vivo binding of 5-HT1a receptors in the KA model of limbic epilepsy in the rat. Epilepsy Res2001 Nov; 47(1–2): 127–139.
111.
HeyesMPWylerARDevinskyOYergeyJAMarkeySPNadiNS. Quinolinic acid concentrations in brain and cerebrospinal fluid of patients with intractable complex partial seizures. Epilepsia1990;31(2): 172–177.
112.
ForutanFEstaljiSBeuMNikolausSHamacherKCoenenHH. Distribution of 5HT2A receptors in the human brain: comparison of data in vivo and post mortem. Nuklearmedizin2002;41(4): 197–201.
113.
StaleyJKKrishnan-SarinSZoghbiSTamagnanGFujitaMSeibylJP. Sex differences in [123l]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse2001;15:41(4): 275–284.
114.
NishizawaSBenkelfatCYoungSNLeytonMMzengezaSde MontignyC. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci U S A1997;13:94(10): 5308–5313.
115.
ParseyRVOquendoMASimpsonNROgdenRTVan HeertumRArangoVMannJJ. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res2002;8:954(2): 173–182.
116.
RabinerEAMessaCSargentPAHusted-KjaerKMontgomeryALawrenceAD. A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: Normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage2002;15(3): 620–632.
117.
ShelineYLMintunMAMoerleinSMSnyderAZ. Greater loss of 5-HT(2A) receptors in midlife than in late life. Am J Psychiatry2002;159(3): 430–435.
118.
TauscherJVerhoeffNPChristensenBKHusseyDMeyerJHKecojevicA. 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. Neuropsychopharmacology2001;24(5): 522–530.
119.
YamamotoMSuharaTOkuboYIchimiyaTSudoYInoueM. Age-related decline of serotonin transporters in living human brain of healthy males. Life Sci2002;5:71 (7): 751–757.
